Hi all, thanks Silverfox for posting it up. I think my comments...

First 18 Last

Share
Profile

Follow
wpaul

15 Posts.

05/09/14

15:38

Post #: 13931776
Share

Originally posted by silverfox3731 ↑

Here below Wpauls great post that got moderated..

I kept it and the one by Quacker as they are a great resource when it comes to undestanding the interim phase 2 trial results in coming months. My comment is that gennocea have set the benchmark with just over a 50% reduction in the frequency of Flairs. Hopefully AHZ can get a 100% reduction but 70 to 80% will be outstanding.

Great to be able to see the views of Julian Chick in Quackers post and welcome WPaul. Your scientific input will be most valuable.

Wpaul post hsv 5 sep.......... "My first time posting and actually the first shares that I ever purchased, so be gentle. I feel like I can shed a little light on the science aspect of vaccines, I’m a published scientific author in HIV vaccines. A therapeutic vaccine doesn't necessarily have to be curative to be therapeutic it can just mediate the virus not necessarily kill it. This is an important distinction particularly when refereeing to herpes viruses as herpes viruses infects nerve cells. The goal of the vaccine was to induce both antibody and T cell responses and the interim results already released stated that only T cells were being generated and hence the definition of therapeutic vaccine. Antibodies can provide protection prior to the virus infecting any cells and is the most important part of a prophylactic vaccine. T cells work by killing the virus infected cell, with herpes infecting nerve cells, you don’t necessarily want to kill the cell or you will have never damage and potentially very server outcomes. Interesting studies in Herpes simplex 1 (not what AHZ have been working on) showed that T cell response didn’t kill the virus but prevented the virus from killing the nerve cells. I believe this is what the therapeutic HSV-2 vaccine is based on is meditating the symptoms and consequently inhibiting the spread of the virus. A therapeutic vaccine may present even better investment opportunities as well as there is the very real potential that it will need to be given multiple times. I personally like the regenerative technology they have and continue to develop which has a lot of potential for future uses. "

Fox

Expand

Hi all, thanks Silverfox for posting it up.

I think my comments in my earlier post directly reflect what quacker posted. I will try and help out whenever there is need for some science explanations but I'm not experienced in business or investing.

AHZ Price at posting: 15.0¢ Sentiment: None Disclosure: Held
11 Upvote

0 Great analysis

Reply

Top Stories

AI stocks: What to expect in 2024-25

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

There are more pages in this discussion • 4 more messages in this thread...

First 18 Last

Add AVR (ASX) to my watchlist

(20min delay)
Last $17.20		Change -0.550(3.10%)		Mkt cap ! $330.6M

Open	High	Low	Value	Volume
$17.75	$17.75	$16.88	$199.1K	11.56K

Buyers (Bids)

No.	Vol.	Price($)
1	500	$17.00

Sellers (Offers)

Price($)	Vol.	No.
$17.24	1000	1

View Market Depth

No.	Vol.	Price($)
1	500	17.000
1	50	16.900
1	5	16.880
1	178	16.850
1	250	16.550

Price($)	Vol.	No.
17.240	1000	1
17.400	1000	1
17.700	50	1
17.750	3388	2
17.800	200	1

Last trade - 16.10pm 17/07/2024 (20 minute delay)

AVR (ASX) Chart

Hi all, thanks Silverfox for posting it up. I think my comments...

AI stocks: What to expect in 2024-25

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Hi all, thanks Silverfox for posting it up. I think my comments...

Top Stories

AI stocks: What to expect in 2024-25

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News